| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Division of Neurology and Neurosurgery (Dr. Boiko), Russian State Medical University, Moscow, Russia; and Division of Neurology and MS Research Programs (Drs. Vorobeychik, Paty, Devonshire, and Sadovnick), The University of British Columbia, Vancouver, Canada.
Address correspondence and reprint requests to Dr. D.W. Paty, Room S195, 2211 Wesbrook Mall, UBCH, Vancouver, British Columbia V6T 2B5, Canada; e-mail: paty{at}interchange.ubc.ca
Objective: To evaluate the clinical course of MS in individuals with onset of MS before age 16.
Methods: Patients with onset of MS before age 16 (n = 116) with complete clinical information on the clinical course from the MS Clinic at The University of British Columbia (UBC) Site Hospital computerized database (MS-COSTAR) were included in this study. The data were compared to those from the Canadian natural history study for MS clinic attendees, regardless of age at onset.
Results: The mean duration of observation was 19.76 ± 0.90 years; the mean age at MS onset was 12.73 ± 0.25 years. Only three cases (2.6%) had a primary progressive (PP) MS course. To date, 60 (53.1%) of 113 subjects have developed secondary progressive (SP) MS. The 50% probability for SPMS was reached 23 years after onset. For patients with relapsing remitting (RR) or SPMS the mean disease duration from onset to the time of confirmed Expanded Disability Status Scale (EDSS) 3.0 was 16.03 ± 1.17 years (at mean age 28.47 ± 1.14); mean duration from onset to the time of EDSS 6.0 was 19.39 ± 1.43 years (at mean age 32.32 ± 1.44). Annual relapse rate was 0.54 ± 0.05 per year. The correlation between the number of relapses during the first year of disease and the course of the disease was also significant.
Conclusions: The prevalence of early onset MS (3.6%) in our study confirms the previous findings on early onset MS. A RR course was seen in the majority of cases of early onset MS. A high frequency of relapses, early age at permanent disability, and the presence of malignant cases raise the question of possible early use of disease-modifying therapy in patients with early onset MS.
This article has been cited by other articles:
|
|
 |
|
  R. F. Neuteboom, M. Boon, C. E. Catsman Berrevoets, J. S. Vles, R. H. Gooskens, H. Stroink, R. J. Vermeulen, J. J. Rotteveel, I. A. Ketelslegers, E. Peeters, et al. Prognostic factors after a first attack of inflammatory CNS demyelination in children Neurology, September 23, 2008; 71(13): 967 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Fisniku, P. A. Brex, D. R. Altmann, K. A. Miszkiel, C. E. Benton, R. Lanyon, A. J. Thompson, and D. H. Miller Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis Brain, March 1, 2008; 131(3): 808 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Renoux, S. Vukusic, Y. Mikaeloff, G. Edan, M. Clanet, B. Dubois, M. Debouverie, B. Brochet, C. Lebrun-Frenay, J. Pelletier, et al. Natural History of Multiple Sclerosis with Childhood Onset N. Engl. J. Med., June 21, 2007; 356(25): 2603 - 2613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Krupp and D. P. Hertz Pediatric multiple sclerosis: Conference Report overview Neurology, April 17, 2007; 68(16_suppl_2): S1 - S2. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Ness, D. Chabas, A. D. Sadovnick, D. Pohl, B. Banwell, B. Weinstock-Guttman, and for the International Pediatric MS Study Group Clinical features of children and adolescents with multiple sclerosis Neurology, April 17, 2007; 68(16_suppl_2): S37 - S45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group Treatment of pediatric multiple sclerosis and variants Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Langer-Gould, R. A. Popat, S. M. Huang, K. Cobb, P. Fontoura, M. K. Gould, and L. M. Nelson Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis: A Systematic Review Arch Neurol, December 1, 2006; 63(12): 1686 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mikaeloff, G. Caridade, S. Assi, S. Suissa, M. Tardieu, and on behalf of the KIDSEP Study Group Prognostic Factors for Early Severity in a Childhood Multiple Sclerosis Cohort Pediatrics, September 1, 2006; 118(3): 1133 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Banwell, A. T. Reder, L. Krupp, S. Tenembaum, M. Eraksoy, B. Alexey, D. Pohl, M. Freedman, L. Schelensky, and I. Antonijevic Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis Neurology, February 28, 2006; 66(4): 472 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Al-Araji and J. Oger Reappraisal of Lhermitte's sign in multiple sclerosis Multiple Sclerosis, August 1, 2005; 11(4): 398 - 402. [Abstract] [PDF]
|
|
|
|
|
|
A Ghezzi, M P Amato, M Capobianco, P Gallo, G Marrosu, V Martinelli, N Milani, C Milanese, L Moiola, F Patti, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study Multiple Sclerosis, August 1, 2005; 11(4): 420 - 424. [Abstract] [PDF]
|
|
|
|
 |
|
 R C Dale and J A Branson Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis? Arch. Dis. Child., June 1, 2005; 90(6): 636 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pohl, K. Rostasy, J. Gartner, and F. Hanefeld Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a Neurology, March 8, 2005; 64(5): 888 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mikaeloff, C. Adamsbaum, B. Husson, L. Vallee, G. Ponsot, C. Confavreux, M. Tardieu, S. Suissa, and the KIDMUS Study Group on Radiology MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood Brain, September 1, 2004; 127(9): 1942 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L J Etheridge, D W Beverley, C Ferrie, and E McManus The use of interferon beta in relapsing-remitting multiple sclerosis Arch. Dis. Child., August 1, 2004; 89(8): 789 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 OTHER ARTICLES NOTED (25 Oct 02 to 17 Jan 03) Evid. Based Nurs., April 1, 2003; 6(2): e1 - 7. [Full Text]
|
|
|
|
 |
|
 I. Bone and G. Fuller NEUROPAEDIATRICS J. Neurol. Neurosurg. Psychiatry, March 1, 2003; 74(90001): i1 - 2. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
